Corcept Therapeutics (NASDAQ:CORT) Issues Earnings Results

Share on StockTwits

Corcept Therapeutics (NASDAQ:CORT) posted its earnings results on Thursday. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.03, Fidelity Earnings reports. The firm had revenue of $81.51 million during the quarter, compared to analysts’ expectations of $77.86 million. Corcept Therapeutics had a net margin of 29.16% and a return on equity of 27.97%. The company’s revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.22 earnings per share.

NASDAQ CORT traded up $0.41 during trading on Friday, reaching $15.01. The company’s stock had a trading volume of 1,863,000 shares, compared to its average volume of 928,963. The stock has a market capitalization of $1.63 billion, a PE ratio of 25.02 and a beta of 1.35. The business has a 50-day moving average price of $14.25 and a 200-day moving average price of $12.18. Corcept Therapeutics has a 1-year low of $9.14 and a 1-year high of $19.48.

A number of analysts have issued reports on the stock. BidaskClub upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, October 29th. TheStreet upgraded shares of Corcept Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, August 16th. Zacks Investment Research upgraded shares of Corcept Therapeutics from a “sell” rating to a “hold” rating and set a $12.00 target price for the company in a research note on Wednesday, July 31st. ValuEngine cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, HC Wainwright assumed coverage on shares of Corcept Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price for the company. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $15.00.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

Read More: What are the benefits of investing in REITs?

Earnings History for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.